Radius Health — Investor Day (April 2022)
45 slides from Radius Health's investor day presentation, Apr 5, 2022

Slide 1: RAD011 Presentation April 5, 2022
RAD011 Presentation April 5, 2022 Exhibit 99.1

Slide 2: Safe Harbor
Safe Harbor RAD011 Presentation - April 5, 2022 2 Any statements made in this presentation relating to future financial or business performance, guidance, conditions, plans, prospects, trends or strategies and other financial or business matters are forward-looking statements within the meaning of t

Slide 3: Today's Speakers
Today’s Speakers RAD011 Presentation - April 5, 2022 3 Jon Foster, Senior Director, Corporate and Product Strategy 10+ years commercial strategy in epilepsy, formerly at Sage Therapeutics Liz Messersmith, PhD, SVP, Neuroscience Group 25+ years of scientific and drug translation experience: CNS and o

Slide 4: Agenda
Agenda RAD011 Presentation - April 5, 2022 4 Section Speaker Page 01 5 02 Science, Data & Clinical Translation 6-12 03 Seizures: Angelman Syndrome (AS) 13-23 04 Hyperphagia: Prader-Willi Syndrome (PWS) 24-35 06 Competitive Landscape & Market Dynamics 38-41 07 Orphan Designation & IP 42-43 08 Summati

Slide 5: Introduction: constituencies and topics to highlight
Constituencies: Patients, caregivers & health care providers Shareholders/creditors and other market participants Employees Topics to highlight: 505(b)(2) clarity from the FDA + single registrational trial ‘Body of evidence’: RAD011 (clinical and pre-clinical), botanical product, literature

Slide 6: Critical assessment factors
Critical assessment factors RAD011 Presentation - April 5, 2022 6 Topic 1 : Product profile of RAD011 – chemistry & formulation, mechanism of action (MOA) and pharmacology. Topic 2: Existing nonclinical, clinical and safety molecule data utilized in asset assessment Topic 3: Pharmaceutical science,

Slide 7: Product Profile: Chemistry & Formulation
Product Profile: Chemistry & Formulation RAD011 Presentation - April 5, 2022 7 Synthetic cannabidiol (CBD)… …oral solution Molecular weight: 314.46 Appearance: white crystalline solid Log P: ~6.5 BCS: Class II Low solubility, high permeability Purity: 99.9%; no psychoactive impurities like THC Drug

Slide 8: Product Profile: Mechanism of Action (MOA)
Product Profile: Mechanism of Action (MOA) RAD011 Presentation - April 5, 2022 8 GABAaR VGCC ENT1/ A1, A2a Also play a role in Seizures Open GABAa channel Open calcium channel ↑ extracellular A inhibits A uptake ↓Glutamate release Hyperphagia Metabolism Anxiety Seizures Prader-Willi syndrome Angelma

Slide 9: Product Profile: Pharmacology
Product Profile: Pharmacology RAD011 Presentation - April 5, 2022 9 Dose & rationale Patients with epilepsy or with PWS: maximum tolerated repeat dose studied is 20mg/kg, BID Absorption RAD011 taken with food to achieve maximum exposure Metabolism Patient populations likely on polypharmacy: potentia

Slide 10: Pre-existing molecule data utilized in asset assessment
Pre-existing molecule data utilized in asset assessment RAD011 Presentation - April 5, 2022 10 Nonclinical Data and pharmacology package to support 505(b)(2) application and clinical activity Clinical Three Phase 1 and Phase 1/2 studies Dose/exposure data Six Phase 2 and open label extension studies

Slide 11: Pharmaceutical Science, CMC and Supply Chain Dynamics
Pharmaceutical Science, CMC and Supply Chain Dynamics RAD011 Presentation - April 5, 2022 11 Benuvia Manufacturing: existing supply agreement and producing clinical supply Proceeding with secondary supply source to support regulatory filings and meet commercial demands Extensive search and selection

Slide 12: Ways to strengthen the underlying quality and positioning of the asset
Ways to strengthen the underlying quality and positioning of the asset RAD011 Presentation - April 5, 2022 12 Clinical Protocols: completed global pivotal protocols for Angelman syndrome (AS) & Prader-Willi syndrome (PWS) Regulatory: Path: obtained FDA agreement / reaffirmation of 505(b)(2) regulato

Slide 13: Angelman Syndrome Symptoms & Manifestations
Angelman Syndrome RAD011 Presentation - April 5, 2022 13 Symptoms & Manifestations Seizures present in 80-95% of patients Highly refractory to medications2 Profound and significant developmental delay Sleep disorder, anxiety, gait abnormality, ataxia Delayed or lack of communication capability Disea

Slide 14: Seizures in Angelman Syndrome
Seizures in Angelman Syndrome RAD011 Presentation - April 5, 2022 14 Seizures among the top two reported symptoms 80-95% of patients suffer from seizures – there are multiple types: Tonic-clonic, tonic or atonic Partial or myoclonic Absence or atypical absence AEDs have not demonstrated safety or ef

Slide 15: Investigational product: to target multiple components of AS
Investigational product: to target multiple components of AS RAD011 Presentation - April 5, 2022 15 RAD011 pivotal study: designed to evaluate effectiveness across core symptomology Frequency of Symptom1 Endpoints Seizures Behavior Sleep Abnormalities >80% Seizure reduction (primary) Vineland2, ABC3

Slide 16: Significant and fundamental unmet medical need: seizure control
Significant and fundamental unmet medical need: seizure control RAD011 Presentation - April 5, 2022 16 Currently, there are no approved therapies for Angelman, and development of new treatments focused on improvements in epilepsy, development and behavior have the potential to make a big difference

Slide 17: RAD011 in AS: rationale and logic
RAD011 in AS: rationale and logic RAD011 Presentation - April 5, 2022 17 CBD MoA: from breadth of data and literature – CBD appears to be a neuronal modulator impacting hyperexcitability via different pharmacological mechanisms Preclinical and existing mouse model data in AS: CBD attenuates seizures

Slide 18: Preclinical: CBD and seizure improvement in AS
Preclinical: CBD and seizure improvement in AS RAD011 Presentation - April 5, 2022 18 Acute CBD: shown to reduce the frequency and severity of seizures in a mouse model of Angelman syndrome Dose dependent reduction in seizures (red columns) and increase in seizure –free percentage (green columns) in

Slide 19: Anti-seizure dose selection: leveraging prior RAD011 data
Anti-seizure dose selection: leveraging prior RAD011 data RAD011 Presentation - April 5, 2022 19 Prior INS011-14-029 Phase 1/2 PK dose cohort study: repeat dosing over 7 days study in epilepsy pediatric patients Dose-dependent anticonvulsant effect seen Three other RAD011 studies: conducted in refra

Slide 20: SCOUT1-019 Study: Phase 3 Design in AS
SCOUT1-019 Study: Phase 3 Design in AS RAD011 Presentation - April 5, 2022 20 1. Synthetic Cannabidiol Oral Solution Trial Design: Double-blind, placebo-controlled study in patients with genetically-confirmed AS Intended to enroll ~225 patients (ages 18 months – 55 years), from ~40 global sites Prim

Slide 21: SCOUT1-019 Study: Phase 3 Design in AS
SCOUT1-019 Study: Phase 3 Design in AS RAD011 Presentation - April 5, 2022 21 1. Synthetic Cannabidiol Oral Solution Phase 3 Design (2:1:1) *Including 3 weeks of dose escalation Additional OLE study (SCOUT-020) planned RAD 011: Synthetic Cannabidiol Oral Solution (CBD) 10, 20, 40 mg/kg/day BID (2:1

Slide 22: Key Angelman syndrome advisors
Key Angelman syndrome advisors RAD011 Presentation - April 5, 2022 22 James Wheless, MD Professor and Chief of Pediatric Neurology University of Tennessee Health Science Center Elizabeth Thiele, MD Director, Pediatric Epilepsy Program Massachusetts General Hospital, Harvard Med School Raman Sankar,

Slide 23: Addressing Community Needs in Rare Disease
Addressing Community Needs in Rare Disease RAD011 Presentation - April 5, 2022 23 Advocacy Groups Supporting Community Awareness With foundations: incorporate relevant and meaningful unmet patient needs into protocol Organizations: appropriate support and study awareness including educating families

Slide 24: Prader-Willi syndrome
Prader-Willi syndrome RAD011 Presentation - April 5, 2022 24 1. Bohonowych et al., “The Global Prader–Willi Syndrome Registry” Genes, 2019. National Institute of Health, “Prader-Willi syndrome” Genetics Home Reference, 2014. 2. Verrotti et al., “Epilepsy in Prader-willi Syndrome: Clinical, Diagnosti

Slide 25: PWS: most significant unmet need – hyperphagia control
PWS: most significant unmet need – hyperphagia control RAD011 Presentation - April 5, 2022 25 Hyperphagia prevents individuals with PWS and their families from enjoying many normal community experiences, and often leads to obesity, the complications of which are the leading causes of death in PWS. P

Slide 26: RAD011 in PWS: rationale and logic
RAD011 in PWS: rationale and logic RAD011 Presentation - April 5, 2022 26 Multifactorial MOA characteristics: supports scientific rationale for treatment of PWS given multiple symptomologies Botanical CBD read-across data: in refractory seizures studies, decreases in appetite and weight have been re

Slide 27: "Reverse engineering" from botanical CBD studies
“Reverse engineering” from botanical CBD studies RAD011 Presentation - April 5, 2022 27 1. Epidiolex FDA Prescribing Information Supportive evidence from a botanically-derived cannabidiol in refractory seizures studies reported appetite suppression in up to 22% of patients versus 5% in placebo1

Slide 28: Scientific evidence for CBD: treatment of core symptoms of PWS
Scientific evidence for CBD: treatment of core symptoms of PWS RAD011 Presentation - April 5, 2022 28 Cannabidiol inhibits hyperphagia induced by CB1 agonist1 Cannabidiol inhibits body weight gain via CB2 receptors2 Subjects with social anxiety disorder (SAD), treatment with cannabidiol results: low

Slide 29: Phase 2 study provided initial data/signals in hyperphagia
Phase 2 study1 provided initial data/signals in hyperphagia RAD011 Presentation - April 5, 2022 29 1. NCT02844933 (discontinued due to prior company insolvency, average 8-10 weeks of treatment) 2. HQ-CT: Hyperphagia Questionnaire for Clinical Trials Efficacy: Change in HQ-CT2 Safety& Tolerability

Slide 30: Lessons learned and incorporated: historical and recent studies
Lessons learned and incorporated: historical and recent studies RAD011 Presentation - April 5, 2022 30 SCOUT-015 Recent Studies* 6 weeks 0-1-2 weeks 24 weeks (maintenance) 8-13 weeks HQ-CT ≥ 13 and HQ-CT difference before randomization HQ-CT ≥ 10 12-65 y.o. 4+ y.o. Key Learnings *Studies used in ana

Slide 31: SCOUT1-015 Study: Phase 2/3 Seamless Design in PWS
SCOUT1-015 Study: Phase 2/3 Seamless Design in PWS2 RAD011 Presentation - April 5, 2022 31 Trial Design: Double-blind, placebo-controlled study in patients with genetically-confirmed PWS Intended to enroll ~200 patients (ages 8-65 years3) across both phases, from 35+ global sites Primary Endpoint: c

Slide 32: SCOUT1-015 Study: Phase 2/3 Seamless Design in PWS
SCOUT1-015 Study: Phase 2/3 Seamless Design in PWS2 RAD011 Presentation - April 5, 2022 32 1. Synthetic Cannabidiol Oral Solution, 2. ClinicalTrials.gov NCT05098509 Phase 2/3 Seamless Design Screening RAD 011: Synthetic Cannabidiol Oral Solution (CBD) 10, 20, 40 mg/kg/day BID (2:1 randomization) Pla

Slide 33: Steps taken to reduce outcome variability
Steps taken to reduce outcome variability RAD011 Presentation - April 5, 2022 33 Patient identification Patient retention HQ-CT training deck/video, periodic documented re-training Interview style at all assessments Appropriate caregiver engagement Reduce intra-patient differences Patient advocacy g

Slide 34: SCOUT-015: Lead Principal Investigators and KOLs
SCOUT-015: Lead Principal Investigators and KOLs RAD011 Presentation - April 5, 2022 34 Principal Investigators KOL Interactions to Date Lynne M. Bird, MD Clinical Geneticist, Rady Children’s Hospital San Diego Tony Goldstone, MA, MRCP, PhD, FTOS Head, PsychoNeuroEndocrinology Research Group Faculty

Slide 35: Addressing Community Needs in Rare Disease
Addressing Community Needs in Rare Disease RAD011 Presentation - April 5, 2022 35 Advocacy Groups Supporting Community Awareness With foundations: incorporate relevant and meaningful unmet patient needs into protocol Organizations: appropriate support and study awareness including educating families

Slide 36: Secondary / other endpoints and symptomologies
Secondary / other endpoints and symptomologies RAD011 Presentation - April 5, 2022 36 Prader-Willi Syndrome Primary Secondary & Other Angelman Syndrome

Slide 37: RAD011: Clinical Translation and Opportunity
RAD011: Clinical Translation and Opportunity RAD011 Presentation - April 5, 2022 37 Neuro-Endocrine Prader-Willi syndrome Creating a Pathway Forward Neuropsychiatry & Neurodevelopment Seizures Genetic Neurodevelopmental Disorders Targets Angelman syndrome Neurology RAD011 Anxiety / Irritability Slee

Slide 38: AS patients: fundamental need for treatment of seizures
AS patients: fundamental need for treatment of seizures RAD011 Presentation - April 5, 2022 38 16-27K patients in US; 80-95% with seizures NO APPROVED products for Angelman syndrome RAD011 will be the most advanced active Angelman clinical program Other AS programs focused primarily on behavioral en

Slide 39: PWS patients: fundamental need to address hyperphagia
PWS patients: fundamental need to address hyperphagia RAD011 Presentation - April 5, 2022 39 22-33K patients in US; nearly all develop hyperphagia NO APPROVED products for hyperphagia RAD011 will be most advanced active clinical stage asset for hyperphagia in PWS Recent late-stage programs experienc

Slide 40: Patient and market dynamics – US
Patient and market dynamics – US RAD011 Presentation - April 5, 2022 40 Angelman Syndrome (AS) Prader-Willi Syndrome (PWS) ~25k patients with AS ~20K patients with seizures ~$800M TAM1 ~25K patients with PWS ~18K adolescents and adults ~1,800M TAM1 80%+ ~70% AS + PWS: a combined estimated market opp

Slide 41: Recent strategic transactions involving single epilepsy assets
Recent strategic transactions involving single epilepsy assets RAD011 Presentation - April 5, 2022 41 Indication March 2021: Takeda acquires remaining stake (50%) of soticlestat for up to $900M PC P1 P2 Dravet Syn. Lennox-Gastaut Syn. P3 App. Lead Indications Dravet Syn. CDKL5 Syn. Indication Jan 20

Slide 42: Intellectual Property
Intellectual Property RAD011 Presentation - April 5, 2022 42 Patent applications granted and pending in US: Formulation compositions of matter (May 2035 estimated expiration) Methods of use (May 2035 estimated expiration) License rights in pending applications directed to: Methods of synthesizing CB

Slide 43: Orphan exclusivity positions
Orphan exclusivity positions RAD011 Presentation - April 5, 2022 43 RAD011 has the potential to receive Orphan Drug regulatory exclusivity of 7 years in the U.S., 10 years in Europe, and 10 years in Japan: Orphan Drug Designation granted by FDA for AS (Feb-22) and PWS (Aug-20) Seeking orphan designa

Slide 44: Goals of call and concluding remarks
Goals of call: primer on our work pre and post asset acquisition Science and clinical inputs from MANY including Harvard MGH, UCSD, UCLA, Imperial College, U of Tenn. Post our RAD011 acquisition: Jazz buys GW Pharma What does that mean to us? Risk/reward assessment and example of thought process

Slide 45: Q&A
Q&A
Source: SEC EDGAR · 8-K filed Apr 5, 2022



